Regulatory Hemophilia gene therapy by CSL and uniQure is now...

Hemophilia gene therapy by CSL and uniQure is now the world’s most expensive medicine

-

The one-time gene therapy from uniQure and CSL Behring called Hemgenix or etranacogene dezaparvovec-drlb has been approved by the FDA, making it the first Hemophilia B gene therapy to receive the FDA green light. With the approval, it also became the most expensive medicine available around the globe with a price tag of $3.5M.

Hemophilia is a blood clotting disorder that is hereditary and generally rare among the population. It is usually treated using clotting protein factor IX injections. Single gene defect causes inadequate production of clotting factor IX, which in turn causes the bodies of the patients to not be able to stop bleeding by themselves.

Matt Kapusta, the CEO of uniQure, labeled it a historic achievement that is backed by over a decade of R&D. He said that the biggest challenge in the development of the therapy was when the company switched Factor IX variant to the Padua-variant from the wild-type FIX. The change called for reasoning, and the team convinced the FDA that even though the change had a substantial impact on patients, it was not big enough for the trial to be restarted.

Kapusta said that one of the reasons for being the first to bring the product forward is that the team was able to swiftly move to the second generation from the first.

The price point of the medicine is very high, but it is not necessarily unforeseen. Previously, FDA approved two rare illness gene therapies developed by bluebird bio, and both were at comparable prices. Skysona, for CALD (Cerebral Adrenoleukodystrophy), had a price tag of $3M while Zynteglo, for beta-thalassemia, stood at $2.8M.

Hemophilia is predominantly found in the male population with a three-year-old study revealing that there were between 6,994 and 7,751 males with the condition in the United States at the time.

A CSL spokesperson stated, “We are confident this price point will generate significant cost savings for the overall healthcare system and significantly lower the economic burden of hemophilia B.”

CSL paid $500M upfront to uniQure according to the deal terms. Royalties and commercial milestone payments could rise to a maximum of $1.5B.

The approval was based on the data from the biggest Hemophilia B trial till now; Hope-B. The data showed that Hemgenix curtailed the rate of annual bleeds. 94% of the patients stopped factor IX prophylaxis and stayed prophylaxis-free.

Therapy-treated patients had a mean factor IX activity of 39% at half a year and 36.7% at 2 years post-dosing. The mean adjusted ABR (annual bleeding rate) was abridged by 54% in 7 to 18 months post-dosing.

Kapusta said that following this, he is now most excited about the Huntington’s disease gene therapy that the company has in the works. He also said that uniQure has the only AAV gene therapy that is being clinically tested at this point and very significant data will be read out in the coming year.

+ posts

Latest news

FDA and CDC exploring unlikely relation between COVID-19 vaccine and stroke

The FDA and CDC have brought out new revelations that the revised COVID-19 injection from Pfizer Inc...

Disappointing sales prompt AstraZeneca to pull out leukemia drug Lumoxiti from U.S. market

In a letter shared with healthcare providers, AstraZeneca has announced that it will be pulling its leukemia...

Sanofi’s Venture Capital units to receive over $750 million in investment to boost firm’s investment capabilities 

After a successful last year in which Sanofi Ventures made its second-highest number of deals, 10 rounds...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you